Anuh Pharma has informed that the Company has been granted the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for Sulfadimethoxine. This approval reinforces Anuh Pharma’s commitment to delivering high-quality Active Pharmaceutical Ingredients that adhere to the most stringent global regulatory standards. The CEP for Sulfadimethoxine will enable expanded access to regulated markets and support our customers with enhanced reliability, compliance, and supply security. The above-mentioned disclosure is available on the Company’s website at www.anuhpharma.com.
The above information is a part of company’s filings submitted to BSE.
